Acquisition Announced
ANI Pharmaceuticals acquisition of Egetis
US$560m consideration
Announced 2026 (approx.)
Advisers
ANI Pharmaceuticals
Acquirer
Not disclosed
- Target
- Egetis
- Acquirer
- ANI Pharmaceuticals
- Target based in
- Sweden
- Buyer based in
- United States
- Sector
- Pharma
- Tags
- Pharma, Rare Disease
In the league tables
Similar deals
- LEO Pharma acquisition of global rights for MT-7117 (dersimelagon) Aug 2026 · US$435m · Pharma
- Chiesi Group acquisition of KalVista Pharmaceuticals Apr 2026 · US$1.9bn · Pharma
- SERB Pharmaceuticals acquisition of Exclusive development and commercialisation rights to Idefirix in Europe and MENA May 2026 · US$134m · Pharma
- Neurocrine Biosciences acquisition of Soleno Therapeutics Apr 2026 · US$2.9bn · Biotech
- Angelini Pharma S.p.A. acquisition of Catalyst Pharmaceuticals May 2026 · US$4.1bn · Pharma
Sources
- 2026 Centerview Partners: Exclusive financial advisor to Egetis on its sale to ANI Pharmaceuticals centerviewpartners.com
